Fibrosis Hepática
The epigenetic roles of pirfenidone – implication in liver disease management
HCV patients with residual fibrosis after DAA treatment re‑establish their epigenetic signature after prolonged release pirfenidone: MINERVA study
Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis
Evaluación no invasiva de pirfenidona de liberación prolongada en cirrosis hepática compensada. Estudio ODISEA, un ensayo aleatorizado.
Noninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial
Identifying and Linking Patients At Risk for MASLD with Advanced Fibrosis to Care in Primary Care
Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Association between elevated fibrosis-4 index of liver fibrosis and risk of hemorrhagic stroke
Pirfenidona de liberación prolongada restaura la expresión de miRNAs y la metilación de islas CpG en pacientes con hepatitis C con respuesta viral sostenida y fibrosis hepática residual
Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
Hepatología clínica y trasplante hepático. Fascículo 1
Predictors for liver fibrosis in non-alcoholic patients with psoriatic diseases: A multicenter cross sectional-study
Cirrhosis etiology trends in developing countries: Transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico
Fibrosis hepática 2022: Necesidades insatisfechas y un plan para el futuro.
Prolonged release pirfenidone pharmacokinetics is modified in cirrhosis GENESIS study.
